$TWOD

Two Harbors Investments Corp (NYSE:TWO) Plans $0.34 Quarterly Dividend

Two Harbors Investments Corp (NYSE:TWO) has declared a quarterly dividend of $0.34 per share, payable on April 15th to shareholders of record on April 2nd, resulting in an annualized yield of 12.6%. The company's dividend payout ratio is 90.7%, indicating potential sustainability concerns, and it recently missed quarterly EPS estimates. Shares are trading near $10.79, with institutional investors owning about 64% of the stock.

Original reporting
MarketBeat · MarketBeat
Published Mar 20, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 20, 2026, 12:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Two Harbors Investments Corp (NYSE:TWO) Plans $0.34 Quarterly Dividend — source image
Decision brief

The 30-second read

$TWODNeutralMed
01

Why it matters

The dividend announcement underscores the company's commitment to income distribution but raises questions about sustainability amid earnings challenges.

02

Market read

The news is relevant for income investors and those with exposure to mortgage REITs, with potential short-term trading opportunities based on dividend yield and earnings performance.

03

What to watch

Potential upcoming earnings revisions or dividend cuts could negatively impact the stock; macroeconomic factors affecting interest rates may influence REIT valuations.

Relevance 6/10Timing: Immediate, as dividend payment date is upcoming on April 15, 2026.

Background

Two Harbors Investments Corp is a mortgage REIT that distributes income through dividends, heavily influenced by interest rate environments and mortgage market conditions.

Company-level read

Ticker impact

$TWODNeutralMedium confidence
Context

The news pertains to Two Harbors Investments Corp's dividend announcement, which is relevant for income-focused investors and dividend traders.

Expected impact

Potential short-term stabilization or slight decline due to earnings miss and high payout ratio; long-term impact uncertain without further earnings improvement.

Evidence & confidence

The dividend announcement is positive for income investors, but recent earnings miss and high payout ratio introduce risk factors that could lead to price volatility.

Market effects

The announcement may influence the mortgage REIT sector, potentially affecting dividend strategies and investor sentiment.

Limited, as the company primarily operates within the U.S. financial markets.

Negligible, as the impact is confined to the regional sector and specific investment community.

Counterpoint

The high dividend yield may be unsustainable given the recent earnings miss and high payout ratio, suggesting caution against aggressive buying.

Key entities

  • Two Harbors Investments Corp

    A mortgage REIT focusing on residential mortgage-backed securities.

Related articles

$TWODHigh

Two Harbors Investment Cor... (TWOD) Stock News

Two Harbors Investment Corp. (TWOD) is offering to repurchase all $115.0 million of its 9.375% Senior Notes due 2030 at $26.3841 per Note, with settlement on October 14, 2026. The offer expires on October 13, 2026, and is expected to total about $121.4 million if all Notes are tendered. Untendered Notes will be redeemed on May 17, 2027, at $25.0130 per Note. TWO plans to delist the Notes from the NYSE and terminate its Exchange Act reporting obligations.

$ONCYMedAI 8/10

ONCOLYTICS BIOTECH INC (ONCY): Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers Pelareorep-driven changes in the tumor microenvironment are associated with tumor responses and shrinkage Immune activation levels

$ONCYMedAI 8/10

Immune-cell expansion accompanied tumor shrinkage in four anal cancer patients

Oncolytics Biotech (ONCY) reported data from a study showing pelareorep, its investigational immunotherapy, increased HPV-16-specific T cells and tumor-infiltrating lymphocytes in anal cancer patients. The treatment, combined with a checkpoint inhibitor, led to tumor shrinkage in four patients, including two complete responses. The Phase 1/2 study is evaluating the safety and efficacy of the combination therapy in unresectable anal cancer patients.

$MGXLowAI 8/10

A potential one-time hemophilia A treatment is planned for a global trial in 2027, pending regulatory clearance.

Metagenomi Therapeutics (MGX) announced preclinical data for MGX-001, a potential one-time treatment for hemophilia A, to be presented at the ASH Annual Meeting. The company plans to initiate a global clinical trial in 2027, pending regulatory approval. MGX-001 aims to insert a Factor VIII gene for sustained production, offering a novel approach to the disease.